Yvonne A. Efebera

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN Primary Analysis

Purpose of the Study: Daratumumab (DARA), a human CD38 mAb, is approved as monotherapy and in combination with standard-of-care (SoC) regimens for MM. In phase 3 studies, DARA-based regim...

Larry D. Anderson Jr.;

Daniela Hoehn ;

Nitya Nathwani ;

Thomas S. Lin ;

Nina Shah ;

Paul G. Richardson ;

Yvonne A. Efebera ;

Caitlin L. Costello , MD;

Andrzej Jakubowiak ;

Tanya M. Wildes ;

Ajai Chari , MD;

Robert Z. Orlowski ;

Peter M. Voorhees , MD;

Kenneth G. Shain ;

Johnathan L. Kaufman ;

Ander J. Cowan ;

Jacob Laubach ;

Sean Murphy ;

Douglas W. Sborov ;

Yana Lutska ;

Brandi Reeves ;

Huiling Pei ;

Cesar Rodriguez ;

Jon Ukropec ;

Rebecca Silbermann ;

Jessica Vermeulen ;

Luciano J. Costa ;

Carla de Boer ;

10/22/2019

Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Relapsed/Refractory Multiple Myeloma Refractory to an IMiD or Proteasome Inhibitor: Updated Analysis of the Phase 1 ANCHOR Study (OP-104)

Purpose of the Study: Despite recent therapeutic advances, multiple myeloma (MM) remains incurable. Melflufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly c...

Yvonne A. Efebera ;

Miquel Granell ;

Paul G. Richardson ;

Roman Hajek ;

Maria-Victoria Mateos ;

Albert Oriol ;

Jacques Delaunay ;

Katell Le Du ;

Jean-Richard Eveillard ;

Lionel Karlin ;

Vladimir Maisnar ;

Joaquin Martinez-Lopez ;